Published: October 23, 2015

InSphero’s CEO Jan Lichtenberg wins Entrepreneur Of The Year™ 2015

InSphero’s CEO Jan Lichtenberg wins Entrepreneur of the Year™ 2015

Schlieren, Switzerland, Oct 23, 2015 – Dr. Jan Lichtenberg, CEO and co-founder of InSphero AG received the Ernst & Young Entrepreneur of the Year™ 2015 award in the category “Emerging Entrepreneur”. 

Dr. Jan Lichtenberg, CEO and co-founder of InSphero AG, has been awarded the Swiss EY Entrepreneur of the Year™ 2015 award for his leadership in building the Schlieren-based 3D cell culture company into a world-leading technology provider that is helping to revolutionize drug development and chemical safety testing.

Watch EY portrait video 

Winners in four categories: Service/Trade, Industry/High-Tech/Life Sciences, Emerging Entrepreneur, and Family Business were selected from 15 finalists by an independent jury and announced this past Saturday. The four winners stood apart for their company achievement, leadership strength, and convincing promotion of their company through professional and social engagement.

Since 1998, EY has tracked successful entrepreneurs in all sectors, branches, regions, and markets within Switzerland. They’re all courageous, innovative, willing to take risks, reliable, engaging, and strong; they are the backbone of the Swiss national economy. EY Entrepreneur of the Year™ is the only entrepreneurial award program with a global dimension, with 60 participating countries around the world honoring entrepreneurial excellence.

A jury will elect the World Entrepreneur of the Year™ from the pool of national winners at the spring 2016 ceremony to be hosted in Monte Carlo.

Other News

News

InSphero Appoints Dr. Olivier Frey as Chief Operating Officer and Chief Technology Officer

InSphero has appointed Dr. Olivier Frey as Chief Operating Officer and Chief Technology Officer, expanding his leadership role as the company continues to grow and scale. With nearly a decade at InSphero and deep expertise across microfluidics, BioMEMS, 3D in vitro models, and organ-on-chip technologies, Olivier will bring technology and operations into closer alignment. In his new role, he will help advance operational efficiency, digitalization, automation, and technology development across the organization.

Read More »
News

InSphero Launches 3D InSight™ DIGIT Platform for Early Gastrointestinal Toxicity Assessment 

InSphero has launched the 3D InSight™ Drug-Induced Gastrointestinal Toxicity (DIGIT) platform, a standardized, high-throughput solution designed to identify gastrointestinal safety liabilities earlier in drug discovery. Combining patient-derived human intestinal organoids, scalable Gri3D® technology, and automated phenotypic imaging, the platform delivers quantitative, decision-ready insights while enabling more consistent and streamlined GI safety assessment.

Read More »
Scroll to Top

Your Success is Our Mission - Get in Touch

Fill in form below to contact our 3D in vitro experts

Sign up for our Newsletter

Get the latest news on 3D in vitro research

View resource

Fill in the form below to view this resource